Report shows MassHealth used clinical rigor, contained costs

11/13/2009

Today, healthcare policy experts at the Massachusetts Health Policy Forum (MHPF) presented findings from a new report on the development and impact of the MassHealth pharmacy program's drug list.

The MHPF study, supported by the Pew Prescription Project, concludes early indications show the Massachusetts model to be a successful and clinically rigorous approach to bending the pharmaceutical cost curve. The authors noted that MassHealth saved at least $99 million in the first year of the MassHealth drug list, which was accepted by most providers with considerable success, and faced limited resistance by advocates.

For more on the forum, visit the MHPF website.